1. Generics Bulletin

Cipla Remains Upbeat On Abraxane As US Generic Competition Looms

Indian Firm Continuing Talks With FDA For Complex ANDA Product

 
• By Dean Rudge

Cipla has provided the latest on its US complex pipeline ahead of several potential launches in the firm’s upcoming 2022/23 financial year. The Indian firm enjoyed 6% group revenue growth in Q3 FY2022 and is on track to hit its EBITDA margin target.

Sales growth concept
GxAbraxane is one of several assets set to boost Cipla's top line • Source: Alamy

While Cipla is in the process of submitting responses to the US Food and Drug Administration for its proposed generic version of Bristol Myers Squibb’s Abraxane (protein-bound paclitaxel), the Indian firm is confident that plenty of opportunity will remain for itself following likely generic market formation by a rival ANDA sponsor in the coming months.

“We believe that the nature of this product may not result in ‘total’ market formation because of the supply [problems] that both the innovator and some of the generic companies

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Generics Bulletin

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.